[{"data":1,"prerenderedAt":210},["ShallowReactive",2],{"drug-asenapine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":51,"contraindications":107,"warnings":117,"renal":132,"monitoring":133,"interactions":134,"review":135,"examples":138,"atc":152,"iran":154,"usApproval":161,"links":167,"populations":184},"asenapine",1,{"fa":7,"en":8},"آسناپین","Asenapine","nervous-system",{"fa":11,"en":12},"ضدروان‌پریشی آتیپیک","Atypical antipsychotic",[14],{"name":15,"market":16},"Saphris","US",[18,19,7],"saphris","سافریس",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"sl-5","sublingual-tablet","sublingual","5 mg sublingual tablet",{"amount":27,"unit":28,"perUnit":29},5,"mg","tablet",[16],[32],{"source":33,"section":34},"fda-saphris","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"sl-10","10 mg sublingual tablet",{"amount":39,"unit":28,"perUnit":29},10,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"sl-2-5","2.5 mg sublingual tablet",{"amount":47,"unit":28,"perUnit":29},2.5,[16],[50],{"source":33,"section":34},[52,77,89],{"id":53,"disease":54,"label":55,"population":58,"type":62,"unit":28,"dose":63,"refs":65,"notes":68},"scz","schizophrenia",{"fa":56,"en":57},"اسکیزوفرنی بزرگسال — ۵ mg زیرزبانی دو بار در روز (حداکثر ۱۰ mg دو بار)","Schizophrenia, adults — 5 mg sublingually twice daily (max 10 mg twice daily)",{"minAge":59},{"value":60,"unit":61},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":64},2,[66],{"source":33,"section":67},"2.2",[69],{"text":70,"refs":73},{"fa":71,"en":72},"زیر زبان حل شود؛ نجوید و نبلعید؛ ۱۰ دقیقه بعد چیزی نخورد و ننوشد. افزایش به ۱۰ mg پس از یک هفته؛ سود بیشتری نشان نداده.","Dissolve under the tongue; do not chew or swallow; no food or drink for 10 min. Increase to 10 mg after one week if tolerated; no added benefit shown.",[74,75],{"source":33,"section":67},{"source":33,"section":76},"2.1",{"id":78,"disease":79,"label":80,"population":83,"type":62,"unit":28,"dose":85,"refs":86},"bp","bipolar-mania",{"fa":81,"en":82},"مانیا یا دوره مختلط دوقطبی I بزرگسال (تک‌درمانی) — ۵ تا ۱۰ mg دو بار در روز","Bipolar I mania or mixed episodes, adults (monotherapy) — 5–10 mg twice daily",{"minAge":84},{"value":60,"unit":61},{"perDose":27,"perDoseMax":39,"dosesPerDay":64},[87],{"source":33,"section":88},"2.3",{"id":90,"disease":79,"label":91,"population":94,"type":62,"unit":28,"dose":97,"refs":98,"notes":100},"bp-child",{"fa":92,"en":93},"مانیای دوقطبی کودک ۱۰ تا ۱۷ سال — شروع ۲٫۵ mg دو بار؛ تا ۱۰ mg دو بار","Bipolar mania, children 10–17 y — start 2.5 mg twice daily; up to 10 mg twice daily",{"minAge":95,"maxAge":96},{"value":39,"unit":61},{"value":60,"unit":61},{"perDose":47,"perDoseMax":39,"dosesPerDay":64},[99],{"source":33,"section":88},[101],{"text":102,"refs":105},{"fa":103,"en":104},"پس از ۳ روز به ۵ mg و پس از ۳ روز دیگر به ۱۰ mg دو بار.","After 3 days to 5 mg, and after 3 more days to 10 mg twice daily.",[106],{"source":33,"section":88},[108],{"id":109,"severity":110,"text":111,"refs":114},"ci","block",{"fa":112,"en":113},"نارسایی شدید کبد (Child-Pugh C)؛ سابقه حساسیت به آسناپین (آنافیلاکسی، آنژیوادم).","Severe hepatic impairment (Child-Pugh C); history of hypersensitivity to asenapine (anaphylaxis, angioedema).",[115],{"source":33,"section":116},"4",[118,125],{"text":119,"refs":122},{"fa":120,"en":121},"هشدار جعبه‌ای: افزایش مرگ در سالمندان مبتلا به سایکوز ناشی از دمانس — برای این کاربرد تأیید نشده.","Boxed warning: increased mortality in elderly patients with dementia-related psychosis — not approved for this use.",[123],{"source":33,"section":124},"Boxed Warning",{"text":126,"refs":129},{"fa":127,"en":128},"سندرم نورولپتیک بدخیم؛ دیسکینزی دیررس؛ تغییرات متابولیک؛ هیپرپرولاکتینمی؛ تشنج؛ دیسفاژی؛ زمین خوردن.","Neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes; hyperprolactinaemia; seizures; dysphagia; falls.",[130],{"source":33,"section":131},"5",[],[],[],{"status":136,"reviewer":137,"date":137},"unverified",null,[139,144,147],{"regimen":53,"formulation":22,"input":140,"expect":143},{"ageYears":141,"weightKg":142},30,70,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},{"regimen":78,"formulation":22,"input":145,"expect":146},{"ageYears":141,"weightKg":142},{"perDose":27,"tabletsPerDoseRounded":5},{"regimen":90,"formulation":44,"input":148,"expect":151},{"ageYears":149,"weightKg":150},12,40,{"perDose":47,"tabletsPerDoseRounded":5},[153],"N05AH05",{"status":155,"refs":156},"not-found",[157],{"source":158,"section":159,"url":160},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Asenapine",{"kind":162,"refs":163,"id":166},"NDA",[164],{"source":33,"section":165},"SPL approval \u002F marketing category","NDA022117",[168,171,175,178,181],{"kind":169,"url":170,"label":166},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022117",{"kind":172,"url":173,"label":174},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8","FDA Saphris",{"kind":176,"url":177,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa610015.html",{"kind":176,"url":179,"label":180},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa620019.html","Asenapine Transdermal Patch",{"kind":182,"url":183,"label":153},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N05AH05",{"pregnancy":185,"pediatric":194,"geriatric":202},{"level":186,"text":187,"quote":190,"refs":191},"caution",{"fa":188,"en":189},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and\u002For withdrawal symptoms.",[192],{"source":33,"section":193},"8.1",{"level":186,"text":195,"quote":198,"refs":199},{"fa":196,"en":197},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and efficacy of SAPHRIS in pediatric patients below the age of 10 years of age have not been evaluated.",[200],{"source":33,"section":201},"8.4",{"level":203,"text":204,"quote":207,"refs":208},"avoid",{"fa":205,"en":206},"برچسب: در سالمندان هشدار جدی یا پرهیز.","Label: serious warning or avoid in older adults.","Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.",[209],{"source":33,"section":124},1792191526810]